NG-BIOTECH
16.7.2021 12:56:10 CEST | Business Wire | Press release
NG Biotech presents Ninonasal®, the COVID-19 antigen self-test that´s detecting Delta and Epsilon variants. Ninonasal® has obtained the CE mark and can now be marketed across Europe.
The highly sensitive Ninonasal® self-test is performed on nasal samples. Ninonasal®´s superior user friendliness supports the comfortable onsite testing, providing reliable results within minutes before leaving home. It even allows the testing of children under the supervision of adults.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210716005156/en/
Different from many other rapid tests, Ninonasal® already confirmed its ability to detect the most important variants of concerns clinically in European hospitals. Its unique test design allows the detection of the Alpha, Beta, Gamma, Delta and Epsilon variants. Therefore, Ninonasal® represents a precious and widely accepted tool for easy and frequent testing to detect positive cases and interrupt infections chains.
Obtaining CE marking
The Ninonasal® rapid test already proofed its performance since April 2021 under the special approval for home use from the French health authority. Now, with its CE mark for home use provided by a German notified body, it can be deployed in Europe within the framework of international distribution agreements.
In France, Ninonasal® is assembled into kits and distributed by Boiron Laboratories in order to strengthen its “fully made in France” character.
Milovan Stankov-Pugès, CEO of NG Biotech, says:
"Facing non-standardized local registration processes and products of doubtful quality and origin, distributors and public institutions across Europe were approaching us for help. With Ninonasal®, we did not just launch another rapid antigen test. It’s a solution for all those who understood that there is finally nothing more expensive than a cheap COVID test
".
About NG Biotech
Founded by a pioneer of the rapid test industry in 2012, NG Biotech is a French family owned company designing and manufacturing innovative in vitro diagnostic tools suitable for decision making in medical emergencies, in the laboratory and at the bedside.
NG Biotech innovation capabilities are powered by an expert R&D team backed by public-private scientific collaborations e.g. with the CEA (the French key player in technological research) and with multiple hospitals across Europe. NG Biotech proposes rapid tests in three main areas: Antimicrobial Resistance, Infectious Disease (COVID-19 tests) and Women's health (blood pregnancy self-tests). Our products are available in more than 70 countries, including Europe, USA and China.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210716005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom